Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 412.5 GBX -1.43% Market Closed
Market Cap: 434.6m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

Intrinsic Value

OXB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OXB stock under the Base Case scenario is 718.92 GBX. Compared to the current market price of 412.5 GBX, Oxford BioMedica PLC is Undervalued by 43%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OXB Intrinsic Value
718.92 GBX
Undervaluation 43%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Oxford BioMedica PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OXB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OXB?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Oxford BioMedica PLC

Provide an overview of the primary business activities
of Oxford BioMedica PLC.

What unique competitive advantages
does Oxford BioMedica PLC hold over its rivals?

What risks and challenges
does Oxford BioMedica PLC face in the near future?

Summarize the latest earnings call
of Oxford BioMedica PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Oxford BioMedica PLC.

Provide P/S
for Oxford BioMedica PLC.

Provide P/E
for Oxford BioMedica PLC.

Provide P/OCF
for Oxford BioMedica PLC.

Provide P/FCFE
for Oxford BioMedica PLC.

Provide P/B
for Oxford BioMedica PLC.

Provide EV/S
for Oxford BioMedica PLC.

Provide EV/GP
for Oxford BioMedica PLC.

Provide EV/EBITDA
for Oxford BioMedica PLC.

Provide EV/EBIT
for Oxford BioMedica PLC.

Provide EV/OCF
for Oxford BioMedica PLC.

Provide EV/FCFF
for Oxford BioMedica PLC.

Provide EV/IC
for Oxford BioMedica PLC.

Show me price targets
for Oxford BioMedica PLC made by professional analysts.

What are the Revenue projections
for Oxford BioMedica PLC?

How accurate were the past Revenue estimates
for Oxford BioMedica PLC?

What are the Net Income projections
for Oxford BioMedica PLC?

How accurate were the past Net Income estimates
for Oxford BioMedica PLC?

What are the EPS projections
for Oxford BioMedica PLC?

How accurate were the past EPS estimates
for Oxford BioMedica PLC?

What are the EBIT projections
for Oxford BioMedica PLC?

How accurate were the past EBIT estimates
for Oxford BioMedica PLC?

Compare the revenue forecasts
for Oxford BioMedica PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Oxford BioMedica PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Oxford BioMedica PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Oxford BioMedica PLC compared to its peers.

Compare the P/E ratios
of Oxford BioMedica PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Oxford BioMedica PLC with its peers.

Analyze the financial leverage
of Oxford BioMedica PLC compared to its main competitors.

Show all profitability ratios
for Oxford BioMedica PLC.

Provide ROE
for Oxford BioMedica PLC.

Provide ROA
for Oxford BioMedica PLC.

Provide ROIC
for Oxford BioMedica PLC.

Provide ROCE
for Oxford BioMedica PLC.

Provide Gross Margin
for Oxford BioMedica PLC.

Provide Operating Margin
for Oxford BioMedica PLC.

Provide Net Margin
for Oxford BioMedica PLC.

Provide FCF Margin
for Oxford BioMedica PLC.

Show all solvency ratios
for Oxford BioMedica PLC.

Provide D/E Ratio
for Oxford BioMedica PLC.

Provide D/A Ratio
for Oxford BioMedica PLC.

Provide Interest Coverage Ratio
for Oxford BioMedica PLC.

Provide Altman Z-Score Ratio
for Oxford BioMedica PLC.

Provide Quick Ratio
for Oxford BioMedica PLC.

Provide Current Ratio
for Oxford BioMedica PLC.

Provide Cash Ratio
for Oxford BioMedica PLC.

What is the historical Revenue growth
over the last 5 years for Oxford BioMedica PLC?

What is the historical Net Income growth
over the last 5 years for Oxford BioMedica PLC?

What is the current Free Cash Flow
of Oxford BioMedica PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Oxford BioMedica PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oxford BioMedica PLC

Current Assets 138.9m
Cash & Short-Term Investments 81.4m
Receivables 36.5m
Other Current Assets 21m
Non-Current Assets 106.1m
PP&E 71.6m
Intangibles 30m
Other Non-Current Assets 4.5m
Current Liabilities 59.1m
Accounts Payable 13m
Accrued Liabilities 13.9m
Other Current Liabilities 32.2m
Non-Current Liabilities 119.6m
Long-Term Debt 105.5m
Other Non-Current Liabilities 14.1m
Efficiency

Earnings Waterfall
Oxford BioMedica PLC

Revenue
97.3m GBP
Cost of Revenue
-61.5m GBP
Gross Profit
35.7m GBP
Operating Expenses
-102.7m GBP
Operating Income
-67m GBP
Other Expenses
-75m GBP
Net Income
-142m GBP

Free Cash Flow Analysis
Oxford BioMedica PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Oxford Biomedica had a transformative 2023, growing client orders from GBP 85 million to GBP 130 million while maintaining a strong cash balance of over GBP 100 million. Revenue grew from GBP 95 million to GBP 104 million by March, with 2024 revenue projected to rise by 40-50% to GBP 126-134 million. The company aims for breakeven in 2024, with long-term plans to double revenue by 2028. Cost reductions saved GBP 30 million annually. Minimal capital expenditures are planned, focusing on transferring platforms strategically without major new investments.

What is Earnings Call?
Fundamental Scores

OXB Profitability Score
Profitability Due Diligence

Oxford BioMedica PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative 3-Years Revenue Growth
19/100
Profitability
Score

Oxford BioMedica PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

OXB Solvency Score
Solvency Due Diligence

Oxford BioMedica PLC's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average D/E
32/100
Solvency
Score

Oxford BioMedica PLC's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OXB Price Targets Summary
Oxford BioMedica PLC

Wall Street analysts forecast OXB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OXB is 489.73 GBX with a low forecast of 308.05 GBX and a high forecast of 777 GBX.

Lowest
Price Target
308.05 GBX
25% Downside
Average
Price Target
489.73 GBX
19% Upside
Highest
Price Target
777 GBX
88% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OXB?

Click here to dive deeper.

Dividends

Oxford BioMedica PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for OXB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

OXB News

Other Videos

Profile

Oxford BioMedica PLC Logo
Oxford BioMedica PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

434.4m GBP

Dividend Yield

0%

Description

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Contact

OXFORDSHIRE
Oxford
Windrush Court, Transport Way
+441865783000.0
www.oxb.com

IPO

1996-11-15

Employees

744

Officers

CEO & Director
Dr. Frank Mathias
CFO & Director
Dr. Lucinda Crabtree Ph.D.
Chief Operating Officer
Mr. Thierry Cournez
Head of Investor Relations
Sophia Bolhassan
General Counsel & Company Secretary
Ms. Natalie Louise Walter
Chief People Officer
Ms. Lisa James
Show More
Chief Innovation Officer
Dr. Kyriacos Mitrophanous Ph.D.
Head of Intellectual Property and Contracts
Ms. Kati Hudson
Chief Business Officer
Dr. Sebastien Ribault
Site Head of UK Operations
Mr. Mark Caswell
Show Less

See Also

Discover More
What is the Intrinsic Value of one OXB stock?

The intrinsic value of one OXB stock under the Base Case scenario is 718.92 GBX.

Is OXB stock undervalued or overvalued?

Compared to the current market price of 412.5 GBX, Oxford BioMedica PLC is Undervalued by 43%.

Back to Top